[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatitis C Market Examined and Forecast in Renub Research Report Recently Published at MarketPublishers.com

21 Sep 2015 • by Natalie Aster

LONDON – Several new hepatitis C drugs have become available over the recent years. Currently, they hold the largest share of the global marketplace. In 2014, the hepatitis C drugs market grew by over USD 12.9 billion from 2013.

Gilead dominates the marketplace, while AbbVie gains prominence by increasing its share in the US. Pharma companies have started to concentrate on introduction of new drugs since several drugs are at present in the pipeline.

In the years to come, the global market is set to grow at a swift pace.

In-demand research report “Hepatitis C Market & Forecast” drawn up by Renub Research offers an in-depth discussion of the global hepatitis C marketplace. The study offers a detailed overview of the market. It covers approved drug sales and sheds light on deals and acquisitions taking place in this lucrative marketplace. The report comprises an analysis of clinical trial by company and pipeline drugs sales forecast.

Report Details:

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
Published: August, 2015
Pages: 87
Price: US$ 1,290.00

More new and discounted reports by the publisher are available at Renub Research page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest